Literature DB >> 10905048

Homeobox genes in leukemogenesis.

C Buske1, R K Humphries.   

Abstract

Considerable progress has been made in unraveling key pathogenetic steps in human leukemogenesis. In recent years, cytogenetic analyses and the molecular characterization of chromosomal breakpoints in patients with acute leukemia have proven that homeobox (HOX) genes, an evolutionarily highly conserved family of transcription factors, are critically involved in human leukemogenesis. HOX genes themselves, as well as their upstream regulators and cofactors, are implicated in the pathogenesis of leukemia, and experimental models using knock-in strategies or retrovirally induced overexpression of candidate genes have shown the leukemogenicity of homeobox genes. This review summarizes the recent advances in this field.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10905048

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  22 in total

1.  The pattern of gene expression in human CD34(+) stem/progenitor cells.

Authors:  G Zhou; J Chen; S Lee; T Clark; J D Rowley; S M Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

3.  Unsuspected role of the brain morphogenetic gene Otx1 in hematopoiesis.

Authors:  Elena Levantini; Alessandra Giorgetti; Francesco Cerisoli; Elisabetta Traggiai; Alessandra Guidi; Richard Martin; Dario Acampora; Peter D Aplan; Gordon Keller; Antonio Simeone; Norman N Iscove; Trang Hoang; Maria Cristina Magli
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-21       Impact factor: 11.205

Review 4.  DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia.

Authors:  Adolfo A Ferrando; A Thomas Look
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

5.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.

Authors:  Olga S Kustikova; Hartmut Geiger; Zhixiong Li; Martijn H Brugman; Stuart M Chambers; Chad A Shaw; Karin Pike-Overzet; Dick de Ridder; Frank J T Staal; Gottfried von Keudell; Kerstin Cornils; Kalpana Jekumar Nattamai; Ute Modlich; Gerard Wagemaker; Margaret A Goodell; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

6.  Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells.

Authors:  Noriko Miyake; Koichi Miyake; Stefan Karlsson; Takashi Shimada
Journal:  Mol Ther       Date:  2010-04-27       Impact factor: 11.454

7.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

8.  Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Authors:  Emma C Collins; Alexandre Appert; Linda Ariza-McNaughton; Richard Pannell; Yoshihiro Yamada; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

9.  High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector.

Authors:  Xiao-Bing Zhang; Brian C Beard; Grant D Trobridge; Brent L Wood; George E Sale; Reeteka Sud; R Keith Humphries; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4.

Authors:  Jon Mar Björnsson; Nina Larsson; Ann C M Brun; Mattias Magnusson; Elisabet Andersson; Patrik Lundström; Jonas Larsson; Ewa Repetowska; Mats Ehinger; R Keith Humphries; Stefan Karlsson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.